Based on phylogenetic analysis, the family of cannabinoid receptors is separated into two different classes of the rhodopsin-like family of GPCRs. While CB1 and CB2 receptors share a group together with lysophospholipid (LPL) and melanocortin receptors (GPCR-A13),  the newly recognized GPR55, GPR119, and GPR18 receptors are officially member of another group (GPCR-A15), together with protein activated receptors (PAR) and other LPL receptors[1]. Two orphan GPCRs have recently been implicated as novel cannabinoid receptors; these are GPR119, which has been proposed as a receptor for oleoylethanolamide, and GPR55 which has been proposed as a receptor activated by multiple different cannabinoid ligands. GPR55 has been demonstrated to interact with chemically unrelated cannabinoid ligands, in both mammalian and non-mammalian recombinant expression systems, and by independent research groups. Clearly, there is some relationship between the ligand-binding sites of GPR55 and CB1/CB2; however, the endogenous agonist and physiological relevance of GPR55 are not yet clear. Studies have suggested that L-α-lysophosphatidylinositol (LPI), which activates GPR55 but not CB1 or CB2 receptors, could be its endogenous ligand. Conversely, cannabidiol (CBD, Axon 1234) is a GPR55 antagonist[2]. GPR119 is strongly implicated in the regulation of energy balance and body weight. However, further corroborating data of the activity of acylethanolamides at GPR119 will be required before it can be regarded unequivocally as a cannabinoid receptor[3].   

[1] P. Joost, A. Methner. Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool for the prediction of orphan receptor ligands. Gen. Biol. 2002, 3, 0063.
[2] S. Sylantyev et al. Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses.Proc. Nat. Acad. Sci. USA 2013, 110, 5193-5198.
[3] A.J. Brown. Novel cannabinoid receptors. Br. J. Pharmacol. 2007, 152, 567-575.

30 Item(s)

per page
Axon ID Name Description From price
1714 (R)-(+)-SLV 319 Inactive enantiomer of SLV 319 €95.00
1235 Abnormal cannabidiol Cannabinoid agonist €135.00
1218 AM 251 CB1 antagonist €95.00
1219 AM 281 CB1 antagonist €95.00
2791 AM 4113 CB1 antagonist €105.00
2541 APD 597 Orally bioavailable selective GPR119 agonist €125.00
2380 APD 668 Potent and selective, orally active GPR119 agonist €125.00
1572 AR 231453 Cannabinoid GPR119 agonist €80.00
3430 AS1269574 Selective and orally available GPR119 agonist €90.00
1234 Cannabidiol GPR55 antagonist €105.00
3955 CB2R PAM C2 First synthetic, potent and orally active CB2 receptor PAM €120.00
2015 CP 945598 CB1 antagonist €135.00
2119 CP 945598 hydrochloride CB1 antagonist €135.00
3097 DBPR211 Potent and selective peripherally restricted CB1 antagonist/inverse agonist €125.00
3632 Genistein CB1 antagonist €70.00
1925 GW 842166X Cannabinoid CB2 receptor agonist €110.00
1440 HU 308 CB2 agonist €140.00
1574 Iodopravadoline CB2 antagonist €75.00
1418 JWH 133 CB2 agonist €110.00
2092 MBX 2982 Potent and selective GPR119 agonist €125.00
1550 MK 0364 CB1 antagonist/inverse agonist €95.00
3028 ML184 Potent and selective GPR55 agonist €120.00
4125 ML193 Highly potent and selective GPR55 antagonist €90.00
1211 Palmitoylethanolamide Endocannabinoid; GPR55 agonist €75.00
1565 PSNCBAM 1 CB1 antagonist (allosteric) €85.00
1712 rac-(±)-SLV 319 Racemate of CB1 antagonist Ibipinabant (Axon 1713) €110.00
1713 SLV 319 CB1 antagonist €105.00
1220 SR 141716 hydrochloride CB1 antagonist €70.00
1924 SR 144528 CB2 receptor antagonist and/or an inverse agonist €95.00
2543 ZCZ 011 Brain penetrant CB1 positive allosteric modulator (PAM) €90.00

30 Item(s)

per page
Please wait...